RCS - Intnl. Biotechnology - Results analysis from Kepler Trust Intelligence

International Biotechnology Trust

08/05/2024 14:47

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240508:nRSH6599Na&default-theme=true

RNS Number : 6599N  Intl. Biotechnology Trust PLC  08 May 2024

International Biotechnology Trust (IBT)

08/05/2024

Results analysis from Kepler Trust Intelligence

IBT's NAV has again beaten the NASDAQ Biotechnology Index during the
six-months ending 29/02/2024. The NAV total return of 11.2% outpaced the index
return of 8.2%. The share price total return per share was 8.7%, marginally
ahead of the index, reflecting widening discounts across the sector.

Increased confidence that the interest rate cycle has peaked led to a change
in investor appetite for risk towards the end of 2023. This has continued into
2024, indicating evidence of a nascent recovery in the biotechnology sector.

The private equity portfolio, which comprised 7.9% of total investments as at
29/02/2024 is primarily represented by two venture capital funds managed by SV
Health. this part of the portfolio has seen some holdings within the venture
capital funds marked down over the interim period.

The Company's dividend policy is to make dividend payments equivalent to 4% of
the Company's NAV, as at the last day of the preceding financial year ending
31 August, through two semi-annual distributions. The first dividend for the
year of 13.9p per share was paid on 26 January 2024, and the Board intends to
declare the second dividend in July 2024 for payment in August 2024.

The board continues to keep the discount to NAV under close review and is
committed to buying back its shares to help manage the position. Although
1,060,776 shares were bought back, the discount widened from 6.3% to 8.7%. As
expected, the ongoing charges ratio has decreased since the transition to
Schroders, reducing from 1.4% to 1.3%.

Chairman of the board Kate Cornish-Bowden said of the managers' move to
Schroders "the integration of the new Manager arrangements has gone well. We
received a positive endorsement of this strategic decision at the AGM in
December 2023, when shareholders voted by over 99% in favour of continuation
of the company".

Kepler View

The Biotechnology sector has suffered three consecutive years of
underperformance, but the green shoots of a recovery are appearing, as
evidenced by the M&A cycle kicking back in. Ailsa and Marek have so far
transitioned to their new management house without any detrimental impact to
performance, which will be gratifying for the board and for shareholders who,
according to the board, expressed a strong desire for continuity when SV
Health took the decision to relinquish the mandate.

We think it noteworthy that the headline NAV performance numbers above
under-play Ailsa and Marek's strong performance from the quoted portfolio,
which rose by 13.1% (gross of management and performance fees) for the
six-month period, outperforming the reference index which returned 8.2%. The
pair passed their three-year anniversary as joint lead-managers on
15/03/2024.  Since taking over the helm, they have delivered a similarly
impressive quoted portfolio NAV total return of 14.7% (1(st) April 2021 to 31
March 2024), well ahead of the reference index which increased by 5.0%, a
period which encompassed a huge amount of volatility.

Ailsa and Marek's approach to investment is pragmatic and valuation-sensitive,
with a strong focus on risk management. Valuations, M&A and the
macroeconomic outlook contributed to the managers making a well-timed move
into small caps in Q4 2023, and while they have since taken some profits and
allowed gearing to fall, Ailsa and Marek maintain a positive outlook for the
sector. The team remains focused on identifying companies with innovative
technologies, strong intellectual property and solid growth potential. IBT has
an actively managed, diversified portfolio, with a team behind it that has
shown it can add value through the highs and lows of sentiment toward this
volatile sector. With the discount to NAV at a historically wide level, those
who share the board's belief that a more benign economic environment and
robust industry fundamentals will give investors greater confidence to invest
in the biotechnology sector, may see this as an opportunity.

CLICK HERE TO READ THE FULL REPORT
(https://www.trustintelligence.co.uk/investor/articles/news-investor-results-analysis-international-biotechnology-trust-retail-may-2024?utm_source=RNS&utm_medium=news)

Visit Kepler Trust Intelligence
(http://www.trustintelligence.co.uk/investor?utm_source=RNS&utm_medium=news)
for more high quality independent investment trust research.

 

Important information

This report has been issued by Kepler Partners LLP.  The analyst who has
prepared this report is aware that Kepler Partners LLP has a relationship with
the company covered in this report and/or a conflict of interest which may
impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of
investments can fall as well as rise and you may get back less than you
invested when you decide to sell your investments. It is strongly recommended
that if you are a private investor independent financial advice should be
taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients.
This report has been issued by Kepler Partners LLP, is based on factual
information only, is solely for information purposes only and any views
contained in it must not be construed as investment or tax advice or a
recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to,
or use by, any person or entity in any jurisdiction or country where such
distribution or use would be contrary to law or regulation or which would
subject Kepler Partners LLP to any registration requirement within such
jurisdiction or country. In particular, this website is exclusively for non-US
Persons. Persons who access this information are required to inform themselves
and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and
should not be construed as, investment advice. No representation or warranty,
express or implied, is given by any person as to the accuracy or completeness
of the information and no responsibility or liability is accepted for the
accuracy or sufficiency of any of the information, for any errors, omissions
or misstatements, negligent or otherwise. Any views and opinions, whilst given
in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation,
offer or solicitation to buy or sell or take any action in relation to any
investment mentioned herein. Any prices or quotations contained herein are
indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or
a connected person may have positions in or options on the securities detailed
in this report, and may buy, sell or offer to purchase or sell such securities
from time to time, but will at all times be subject to restrictions imposed by
the firm's internal rules. A copy of the firm's Conflict of Interest policy is
available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS
(http://www.trustintelligence.co.uk/investor/terms?utm_source=RNS&utm_medium=news)

Kepler Partners LLP is authorised and regulated by the Financial Conduct
Authority (FRN 480590), registered in England and Wales at 70 Conduit Street,
London W1S 2GF with registered number OC334771.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADZGGKFRKGDZM